KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Net Income (2018 - 2025)

Vir Biotechnology's Net Income history spans 8 years, with the latest figure at -$42.9 million for Q4 2025.

  • For Q4 2025, Net Income rose 58.96% year-over-year to -$42.9 million; the TTM value through Dec 2025 reached -$438.0 million, up 16.09%, while the annual FY2025 figure was -$438.0 million, 16.09% up from the prior year.
  • Net Income for Q4 2025 was -$42.9 million at Vir Biotechnology, up from -$163.1 million in the prior quarter.
  • Across five years, Net Income topped out at $525.3 million in Q4 2021 and bottomed at -$213.7 million in Q3 2024.
  • The 5-year median for Net Income is -$107.8 million (2024), against an average of -$26.6 million.
  • The largest YoY upside for Net Income was 407.04% in 2022 against a maximum downside of 225.47% in 2022.
  • A 5-year view of Net Income shows it stood at $525.3 million in 2021, then plummeted by 119.34% to -$101.6 million in 2022, then fell by 14.14% to -$116.0 million in 2023, then rose by 9.82% to -$104.6 million in 2024, then skyrocketed by 58.96% to -$42.9 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Net Income are -$42.9 million (Q4 2025), -$163.1 million (Q3 2025), and -$111.0 million (Q2 2025).